MRNA
NASDAQ
$59.49
Moderna Inc (MRNA)
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Hold
Target: $48.26 (-18.88%)
Market Cap
$27B
Free Cash Flow Yield
-5.91%
Beta (5Y)
1.37
Price Chart
Valuation
Market Cap$27B
Forward P/E23.04
P/S12.18
P/B3.61
Profitability
Total Revenue (TTM)$2.23B
Gross Profit (TTM)-$1.56B
EBITDA-$3.18B
Profit Margin-143.5%
Operating Margin-131.1%
EPS-$8.11
Financial Health
Debt-to-Equity8%
Free Cash Flow Yield-5.91%
Growth & Risk
Revenue 5Y CAGR-4.02%
Beta (5Y)1.37
Sharpe Ratio1.17